London, Jan 6, 2026, 10:52 GMT — Regular session
- IMI shares down about 0.4% at 2,514p; intraday range 2,512p–2,534p
- Company calendar flags full-year results on March 6, then annual report March 31 and a Q1 update/AGM on May 12
- Analysts tracked by IMI forecast 2026 revenue of £2.36 bln and adjusted operating profit of £482 mln
IMI plc stock slipped on Tuesday, with shares down about 0.4% in mid-morning London trading, as the industrial engineer lacked an immediate company catalyst.
That matters because IMI is trading near the top end of its recent range after a strong run into year-end. When valuations stretch, even small wobbles can hint at a shift from momentum to fundamentals.
The next scheduled update is not far off. IMI’s full-year results in early March will set expectations for order intake — the value of new orders booked — and margins heading into 2026.
IMI IMI.L was shown at 2,514 pence, down 10 pence on the day, after opening at 2,522p, according to data on lse.co.uk. The stock traded between 2,512p and 2,534p and the feed showed no new regulatory announcements.
IMI says it is a global leader in fluid and motion control, with end markets tied to long-term trends in energy, automation and healthcare. Its investor calendar lists full-year results for 2025 on March 6, followed by the annual report on March 31 and a Q1 trading update alongside its AGM on May 12.
In wider markets, the STOXX 600 was up 0.2% by 0922 GMT, with Germany’s DAX and Spain’s IBEX at record highs, Reuters reported. “We’re becoming a bit inured to the environment of heightened uncertainty,” said Matthew Sherwood, senior global economist at the Economist Intelligence Unit. Reuters
Goldman Sachs raised its 12-month target for the STOXX 600 to 625 and lifted its year-end FTSE 100 forecast to 10,400, pointing to improving earnings and lower valuations than U.S. stocks. It warned that a weaker dollar could weigh on Europe.
Analyst forecasts compiled by IMI, last updated on Dec. 18, put 2026 group revenue at £2.36 billion and adjusted operating profit at £482 million, with an adjusted operating margin of 20.4%. Adjusted results exclude one-offs, giving a clearer view of the underlying business; the same consensus shows 2026 adjusted EPS of 140.7 pence.
At Tuesday’s levels, that implies a forward price-to-earnings multiple of about 18 on 2026 estimates. Investing.com shows IMI’s 52-week range at 1,558p to 2,572p and an average 12-month price target around 2,781p — about 11% above current levels.
But the downside risk is a softer orders picture if customers delay automation spending or if healthcare-related demand stays uneven. Any guidance that points to slower growth would put pressure on a stock priced for steady delivery.
